Law360, New York (April 8, 2008, 12:00 AM EDT) -- In another attempt to block a generic version of its osteoporosis drug Actonel from the market, Procter & Gamble fired off a third suit against Teva Pharmaceutical Industries Ltd. Friday, again alleging infringement of its patent for Actonel's active ingredient.
The complaint, lodged in the U.S. District Court for the District of Delaware, responds to an abbreviated new drug application filed by Teva for a 35 mg form of generic Actonel co-packaged with calcium carbonate tablets.
Procter & Gamble has two other suits pending before the...
P&G Files A Third Suit To Stop Generic Actonel
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
